On January 8, 2013, Health Canada issued the import license required to bring MDMA from Switzerland into Canada for our upcoming Canadian study of MDMA-assisted psychotherapy for PTSD. The Canadian Institutional Review Board (IRB) approved the protocol on November 7, 2008, and Health Canada cleared the study on March 17, 2009. Since then, it has taken us almost four years to satisfy Health Canada’s pharmacy security requirements and obtain the import permit for nine grams of MDMA. We anticipate that obtaining the Swiss export permit will take a few weeks. Once the MDMA has arrived in Canada, we will submit a series of minor protocol revisions to Health Canada and to the Institutional Review Board. Once they are approved, which could take about a month, we will begin screening and treating subjects.
